Taoiseach doesn't commit to timeline for approval of drug to treat Friedreich's ataxia
The Taoiseach, Micheál Martin, acknowledged the urgency of assessing a drug, Skyclarys, for treating Friedreich’s ataxia but did not commit to a specific timeline for approval. Friedreich’s ataxia is a progressive, hereditary neuromuscular disorder affecting the nervous system and heart. While Skyclarys has been approved by the European Medicines Agency and is available in other European countries, it remains inaccessible to approximately 200 patients in Ireland. A Cork father, Craig Coady, whose son died from the disease and whose other son suffers from it, reported receiving minimal information after an HSE meeting discussing the drug’s pricing and reimbursement. The decision will be reviewed by the HSE Rare Diseases Technology Review Committee, which includes healthcare professionals and patient representatives. Coady expressed concern over his son’s worsening condition and emphasized the need for urgent action. Sinn Féin’s health spokesperson called for an expedited review, highlighting the risks of delaying treatment for patients with a rapidly progressing disease.
How each side covered it
The same event, grouped by the political lean of the outlets covering it.
progressive
center
conservative
★
How each side covered it
Support independent, bias-aware news and unlock the social pulse, community voting, and your personalized For You feed.
The Taoiseach, Micheál Martin, acknowledged the urgency of assessing a drug, Skyclarys, for treating Friedreich’s ataxia but did not commit to a specific timeline for approval. Friedreich’s ataxia is a progressive, hereditary neuromuscular disorder affecting the nervous system and heart. While Skyclarys has been approved by the European Medicines Agency and is available in other European countries, it remains inaccessible to approximately 200 patients in Ireland. A Cork father, Craig Coady, whose son died from the disease and whose other son suffers from it, reported receiving minimal information after an HSE meeting discussing the drug’s pricing and reimbursement. The decision will be reviewed by the HSE Rare Diseases Technology Review Committee, which includes healthcare professionals and patient representatives. Coady expressed concern over his son’s worsening condition and emphasized the need for urgent action. Sinn Féin’s health spokesperson called for an expedited review, highlighting the risks of delaying treatment for patients with a rapidly progressing disease.
Bias read (Center): The article presents a balanced account of the situation, focusing on the lack of commitment from the Taoiseach and the concerns raised by both families and politicians. There is no overt ideological framing or emphasis on one political side over another. The focus is on the procedural delays and un
Friedreich's Ataxia patients in Ireland have expressed frustration over the delayed approval of the medication Skyclarys, which has been approved in other EU countries. During a session in the Dáil, Sinn Féin health spokesperson David Cullinane criticized the HSE Drugs group for deferring its recommendation on the treatment, emphasizing the urgent need for patients who suffer from this rare, progressive, and life-limiting condition. The Taoiseach acknowledged the emotional impact on affected families but stressed the importance of adhering to scientific evaluation processes. He committed to working with opposition parties to find a solution.
Bias read (Progressive): The article frames the delay in approving Skyclarys as a failure to prioritize patient needs, using emotionally charged language like 'treated appallingly' and highlighting the trauma experienced by families. While the Taoiseach acknowledges the urgency, the emphasis on patient suffering and the use
Campaigners and patients with Friedreich's Ataxia have criticized the ongoing delays in the reimbursement decision for Skyclarys, the only EU-approved treatment for the rare condition. The HSE Drugs Group rejected the drug for public funding and referred the application to the Rare Diseases Technology Review Committee (RDTRC) for further review. Friedreich's Ataxia is a progressive neurological disorder that affects mobility and coordination, and clinical trials show Skyclarys may slow symptom progression. While the drug is publicly funded in several European countries, the National Centre for Pharmacoeconomics (NCPE) previously recommended against reimbursement due to concerns over cost-effectiveness and long-term healthcare sustainability. Patients like Emily Felix, who has lived with the condition since age 12, describe the delays as heartbreaking, emphasizing the urgency of accessing treatment as the condition worsens. The HSE stated it aims to complete the RDTRC review within one month.
Bias read (Center): The article presents the situation from multiple perspectives, including patient advocacy, HSE procedures, and the NCPE's economic evaluation criteria. It does not overtly favor any political ideology or party, nor does it take a clear editorial stance beyond reporting the controversy around delayed
★
Keep the news honest.
ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €5/month.
Ireland
